Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.51 |
| ▸ | RORC | P51449 | 12/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL180435 | 0.83 | USP30 (0.56) | USP30STSGPR119 | |
| SCHEMBL16611368 | 0.82 | RORC (0.43) | RORCSTSGPR119 | |
| SCHEMBL30726423 | 0.82 | RORC (0.55) | RORCSTSGPR119 | |
| SCHEMBL35211565 | 0.82 | STS (0.52) | RORCSTSGPR119 | |
| SCHEMBL23538696 | 0.82 | ALDH1A1 (0.44) | RORCSTSGPR119 | |
| SCHEMBL23291509 | 0.82 | RORC (0.55) | RORCSTSGPR119 | |
| SCHEMBL16936643 | 0.81 | USP30 (0.59) | USP30GPR119 | |
| SCHEMBL16874571 | 0.81 | ALDH1A1 (0.55) | STSGPR119 | |
| SCHEMBL16874573 | 0.81 | ALDH1A1 (0.55) | STSGPR119 | |
| SCHEMBL23538342 | 0.80 | ALDH1A1 (0.54) | RORCSTSGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814351-A1 | COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-05-05 | — | — | EP | disclosed |
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2016-09-01 | — | — | US | disclosed |
| US-9371320-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-21 | — | — | US | disclosed |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-21 | — | — | US | disclosed |
| EP-2857400-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251352-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | USP30 570/4885RORC 538/4885STS 1122/4885 |
| US-20150141406-A1 | HETEROCYCLIC COMPOUND | JAK2, JAK1, STAT3 | USP30 570/4885RORC 538/4885STS 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.